findmyKOL
Clinical trialNCT02134886TerminatedPhase 1Interventional

Erlotinib Hydrochloride in Treating Non-Small Cell Lung Cancer That is Metastatic or Cannot be Removed by Surgery in Patients With HIV Infection

SponsorNational Cancer Institute (NCI)Enrollment48HIV InfectionRecurrent Non-Small Cell Lung CarcinomaStage IIIA Non-Small Cell Lung CancerStage IIIB Non-Small Cell Lung CancerStage IV Non-Small Cell Lung Cancer
View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This phase I trial studies the side effects and best dose of erlotinib hydrochloride in treating non-small cell lung cancer that has spread to other parts of the body or cannot be removed by surgery in patients with human immunodeficiency virus (HIV) infection. Erlotinib hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Erlotinib hydrochloride is a standard drug used for treating lung cancer, however, it is not yet known whether it is safe to give erlotinib hydrochloride to patients who also have HIV infection or not.
clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

5 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States
  • Ucla Center for Clinical Aids Research and Education

    Los Angeles, California, United States

  • University of California San Diego

    San Diego, California, United States

  • Albert Einstein College of Medicine

    The Bronx, New York, United States

  • Montefiore Medical Center - Moses Campus

    The Bronx, New York, United States

  • Montefiore Medical Center-Einstein Campus

    The Bronx, New York, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Erlotinib →
Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
31 Jul 2014
Primary completion
30 Sept 2015
Completion
30 Sept 2015
Last update posted
6 Oct 2015
Registered enrollment
48
Registry id
NCT02134886
clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.